Abstract
BackgroundNatalizumab (NAT) is a recombinant humanised anti-α4-integrin antibody used in treating Relapsing Remitting (RR) Multiple Sclerosis (MS).Purpose To evaluate the long-term safety and efficacy of NAT in Cypriot patients, to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European Journal of Hospital Pharmacy: Science and Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.